With a PhD in biochemistry and physiology, Thierry Jean has joined CNRS in 1988. He created Cerep, a service provider in drug screening and profiling, in 1990 and served as President and CEO until 2013, when it was acquired by Eurofins. Thierry Jean joined Eurofins as Senior VP Drug Discovery in 2013. In 2014, Thierry Jean created Levitha, a consulting company for pharmaceutical companies, specialized in laboratory and R&D organization.
Thierry Jean contributed in 2020 to the creation of MImAbs of which he acts now as President and CEO.
Professor of immunotechnology at Aix-Marseille University (AMU) and co-founder of Innate Pharma, François Romagné contributed to the creation of MImAbs, where he has been the Scientific Director ever since. He brings his knowledge and his experience of antibodies, both in diagnostics (14 years spent within the immunodiagnostic company Immunotech) and in therapeutic applications (14 years as Chief Scientific Officer of Innate Pharma of whom he is now members of Scientific Advisory Board).
François is the author of over 50 scientific publications and 15 patents.
Stéphanie Blanchin boasts a long experience in development and characterization of monoclonal antibodies for diagnostics (CHU de Caen) as well as therapeutic purposes (PX'Therapeutics). After her PhD in Immunology at Aix-Marseille Université (AMU), she pursued a postdoctoral internship in the Department of Medical Biochemistry at Cardiff University before joining the laboratory of Immunology and immunopathology of the CHU of Caen. Building on her experience and before joining MImAbs, she started and directed a platform dedicated to the generation of therapeutic monoclonal antibodies within the biotechnology company PX’Therapeutics.
Laurent POUYET has a long experience using in vitro and in vivo models for the validation of drug candidates in cancer and inflammation. He holds a PhD in Immunology from Aix-Marseille Université (AMU) during which he worked at the Immunology Center of Marseille-Luminy (CIML). Laurent POUYET was then a postdoctoral fellow first at the University of California San Francisco (UCSF), thenat the Marseille Cancer Research Center (CRCM) where he developed several models to reproduce the biological mechanisms involved in cancer and inflammatory diseases. Building on his experience, he worked at TrGET, the pre-clinical assay platform of the Paoli-Calmettes Institute (IPC) before joining MImAbs.
Patrick VLIEGHE holds a Ph.D. degree in Medicinal Chemistry and a Master’s degree specialized in Healthcare Company Management at Euromed Management (now KEDGE Business School). He has over 20 years of experience in pharma/biotech, technology transfer and financing of innovation, working notably on various projects at the interface of science and business development. Among several experiences, he was Head of Development at Vect-Horus (a drug targeting company), and Technology Transfer Manager (SATT Sud-Est, a Technology Transfer Office).